The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 3×
“Distribution of change from baseline (letters) [median (quartiles)] 3 wks 2 ( 7, 3) 5 ( 1, 8) 6 wks 1 ( 6, 6) 5 ( 2, 12 9 wks 3 ( 5, 6) 7 ( 2, 10 12 wks 1 ( 6, 5) 5 ( 1, 12 Change from baseline [n (%)] 3 wks 15-letter improvement 1 (6) 1 (5) 10-letter improvement 1 (6) 4 (19) Within 9 letters 16 (89) 16 (76) 10 letter…”
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Early Photocoagulation for Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38011-7 · Cited by 1,259
Intravitreal triamcinolone for refractory diabetic macular edema
Martidis, A., Duker, J. S., Greenberg, P. B., Rogers, A. H., Puliafito, C. A., Reichel, E., & Baumal, C. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)00975-2 · Cited by 1,032
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.06.052 · Cited by 614
A computerized method of visual acuity testing
Beck, R. W., Moke, P. S., Turpin, A. H., Ferris, F. L., SanGiovanni, J. P., Johnson, C. A., Birch, E. E., Chandler, D. L., Cox, T. A., Blair, R. C., et al. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01825-1 · Cited by 607
Cited by
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0493 · Cited by 720
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Kaur, C., Foulds, W. S., & Ling, E. A. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.09.003 · Cited by 470
Association of Vitreous Inflammatory Factors with Diabetic Macular Edema
Funatsu, H., Noma, H., Mimura, T., Eguchi, S., & Hori, S. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.09.037 · Cited by 451
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Krohne, T. U., Eter, N., Holz, F. G., & Meyer, C. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.036 · Cited by 363
Ocular complications of diabetes mellitus
Sayin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.92 · Cited by 358
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304
Gupta, N., Mansoor, S., Sharma, A., Sapkal, A., Sheth, J., Falatoonzadeh, P., Kuppermann, B., & Kenney, M. (2013) · The Open Ophthalmology Journal · doi:10.2174/1874364101307010004 · Cited by 285
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Diabetic retinopathy and systemic vascular complications
Cheung, N., & Wong, T. Y. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.001 · Cited by 269
Virgili, G., Menchini, F., Casazza, G., Hogg, R., Das, R. R., Wang, X., & Michelessi, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008081.pub3 · Cited by 265
Microvascular complications and diabetic retinopathy: recent advances and future implications
Barot, M., Gokulgandhi, M. R., Patel, S., & Mitra, A. K. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.206 · Cited by 92
Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema
Stein, J. D., Newman-Casey, P. A., Kim, D. D., Nwanyanwu, K. H., Johnson, M. W., & Hutton, D. W. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.002 · Cited by 65
Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912603 · Cited by 6
Metadata
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 114
- Issue
- 10
- Pages
- 1860-1867.e7
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W1559170621
- Cited by
- 451
- References
- 26
- FWCI
- 34.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.